Catalio Capital Management announced the closing of its fourth venture fund, Catalio Nexus Fund IV, with commitments exceeding $400 million across the Fund and its related co-investment vehicles. The fund received substantial backing from existing Catalio investors as well as new global institutional investors, RIAs, foundations, and endowments.
This fundraising achievement represents a significant milestone for Catalio, underscoring investor confidence in its distinctive strategy of supporting breakthrough biomedical technology companies founded by serial scientist-entrepreneurs.
Established in 2020 by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, the firm manages $2 billion in assets across private equity, private credit, and public equities strategies.
Catalio’s core investment approach focuses on identifying and supporting transformative healthcare companies emerging from leading academic institutions, led by repeat founders with deep scientific expertise. And its Nexus funds have supported more than 80 private companies since the firm’s founding five years ago, with several businesses having been sold or taken public over the years, yielding distributions to limited partners annually since the firm’s inception.
So far, Fund IV has made 16 investments, and some recent highlights in Fund IV include:
1.) Co-leading PinkDx’s $40 million Series A fundraise aimed at developing diagnostics for gynecological cancers, building on Catalio’s extensive track record of success in cancer diagnostics.
2.) Investing in the Series A financing of Superluminal Medicines, augmenting Catalio’s portfolio of AI-enabled drug discovery companies.
3.) Launching two new companies focused on immunology and inflammation: Rhapsogen (co-founded by Catalio Venture Partner Dr. Jeffrey Ravetch at Rockefeller University) and TBD Pharma (co-founded by Catalio Venture Partner Dr. Bert Vogelstein at Johns Hopkins University).
4.) Taking advantage of attractive valuations in late-stage companies by participating in the $150 million Series E financing for Imperative Care, a medical device company; a PIPE for Protara Therapeutics, an oncology company; and the $180 million Series D financing for Alentis Therapeutics, a company developing antibody drug conjugates (ADC) for oncology indications.
KEY QUOTES:
“We are grateful for the continued confidence and strong support we received for Fund IV from both new and existing high caliber investors. These new funds will allow Catalio to continue taking advantage of opportunities in a historic buyer’s market in biotech, and to keep distinguishing ourselves as a leading innovative healthcare investor around the globe.”
Olga Maltseva, Partner & Head of Operations at Catalio, who oversees the firm’s marketing division
“We continue to see many compelling investment opportunities in this current market, including deals with prospects for near-term liquidity and deals with prospects for long-term growth. We are proud to invest in breakthrough biomedical technology companies developing drugs, devices, diagnostics, and tools that have potential for broad clinical impact and can enhance the lives of millions of patients around the world while delivering meaningful returns for our investors.”
Dr. Diamantis Xylas, Partner & Head of Research at Catalio
